# Omega-3-Acid Ethyl Esters 90 Soft Capsules for Lowering Very High Triglycerides

Study · id `cardio:ct-nct02625870` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02625870](<https://clinicaltrials.gov/study/NCT02625870>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02625870

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 240 participants.

## Technical summary

Registry record NCT02625870. Randomized; double masking; primary purpose treatment. Start 2015-12 (registry gives no type); primary completion 2016-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 240 participants (planned count; ClinicalTrials.gov record NCT02625870, source copy `cardio:ctgov-nct02625870-2015-12-09`, retrieved 2026-10-31)
- Start date: 2015-12 (registry gives no type) (ClinicalTrials.gov record NCT02625870, source copy `cardio:ctgov-nct02625870-2015-12-09`, retrieved 2026-10-31)
- Primary completion: 2016-12 (anticipated) (ClinicalTrials.gov record NCT02625870, source copy `cardio:ctgov-nct02625870-2015-12-09`, retrieved 2026-10-31)
- Completion: Not reported
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02625870-2015-12-09`, retrieved 2026-10-31)

## The registry's words

- Brief title: Omega-3-Acid Ethyl Esters 90 Soft Capsules for Lowering Very High Triglycerides
- Acronym: OMEELVHT
- Condition: Hypertriglyceridemia
- Intervention (Drug): Omega-3-Acid Ethyl Esters 90 Soft Capsules
- Intervention (Drug): Corn Oil
- Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High triglycerides (`cardio:hypertriglyceridemia`)
- Registry lists this organization as the lead sponsor: Jiangsu HengRui Medicine Co., Ltd. (`cardio:org-jiangsu-hengrui-medicine-co-ltd`)

## Provenance

Content hash: 416504c7a2d325287b3c52468443fd5290c25c73635c568ac93bdf5bc0337a4c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
